Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Considerations for dofetilide use in the elderly.

Crist LW, Dixon DL.

Consult Pharm. 2014 Apr;29(4):270-4. doi: 10.4140/TCP.n.2014.270.

PMID:
24704896
2.

Chemical cardioversion of atrial fibrillation with intravenous dofetilide.

Sedgwick ML, Lip G, Rae AP, Cobbe SM.

Int J Cardiol. 1995 Apr;49(2):159-66.

PMID:
7628887
3.

Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation.

Denetclaw TH, Oshima N, Dowling TC.

Ann Pharmacother. 2011 Jul;45(7-8):e44. doi: 10.1345/aph.1Q159. Epub 2011 Jun 28.

PMID:
21712508
4.

Dofetilide for atrial fibrillation.

[No authors listed]

Med Lett Drugs Ther. 2000 May 15;42(1078):41-2. No abstract available.

PMID:
10847114
5.

Dofetilide: a new class III antiarrhythmic agent.

Roukoz H, Saliba W.

Expert Rev Cardiovasc Ther. 2007 Jan;5(1):9-19. Review.

PMID:
17187453
8.

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.

Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ.

N Engl J Med. 1999 Sep 16;341(12):857-65.

9.
10.

Phase IV trial evaluating the effectiveness and safety of dofetilide.

Guanzon AV, Crouch MA.

Ann Pharmacother. 2004 Jul-Aug;38(7-8):1142-7. Epub 2004 May 25.

PMID:
15161945
12.

Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.

Brumberg G, Gera N, Pray C, Adelstein E, Barrington W, Bazaz R, Mendenhall GS, Nemec J, Voigt A, Wang NC, Schwartzman D, Saba S, Jain SK.

Am J Cardiol. 2013 Aug 15;112(4):505-8. doi: 10.1016/j.amjcard.2013.04.014. Epub 2013 May 22.

PMID:
23706388
13.

Dofetilide: a review of its use in atrial fibrillation and atrial flutter.

McClellan KJ, Markham A.

Drugs. 1999 Dec;58(6):1043-59. Review.

PMID:
10651390
15.

Practical approach to the use and monitoring of dofetilide therapy.

Tran A, Vichiendilokkul A, Racine E, Milad A.

Am J Health Syst Pharm. 2001 Nov 1;58(21):2050-9.

PMID:
11715827
16.

Dofetilide-induced long QT and torsades de pointes.

Aktas MK, Shah AH, Akiyama T.

Ann Noninvasive Electrocardiol. 2007 Jul;12(3):197-202.

PMID:
17617063
17.

Atypical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes.

Reiffel JA.

Pacing Clin Electrophysiol. 2005 Aug;28(8):877-9.

PMID:
16105020
19.

Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.

Abraham JM, Saliba WI, Vekstein C, Lawrence D, Bhargava M, Bassiouny M, Janiszewski D, Lindsay B, Militello M, Nissen SE, Poe S, Tanaka-Esposito C, Wolski K, Wilkoff BL.

Circ Arrhythm Electrophysiol. 2015 Aug;8(4):772-6. doi: 10.1161/CIRCEP.114.002339. Epub 2015 Jun 10.

20.

Initiation and monitoring of class III antiarrhythmic agents.

Freeland S, Worthy C, Zolnierz M.

J Cardiovasc Electrophysiol. 2003 Dec;14(12 Suppl):S291-5.

PMID:
15005217

Supplemental Content

Support Center